Patent · US Active

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

US11066457B2 · kind B2 · utility

4Cited by

7References

8Claims

0Family size

Assignee

CELLULAR BIOMEDICINE GROUP HK LIMITED · CN

Inventors

Yihong Yao · Boyds, US
Jiaqi Huang · Rockville, US
Shigui ZHU · Hong Kong, CN
Wei Zhu · Shanghai, CN
Xin Yao · Beijing, CN
Zhiyuan Li · Nanhu, CN
Li Zhang · Miaocheng, CN
Lin Zhu · Lexington, US
Anyun MA · Hong Kong, CN
Yutian WEI · Shanghai, CN
Yanfeng Li · Beijing, CN
Qingxia Wang · Shanghai, CN
Jiaping HE · Hong Kong, CN

Key dates

Filing date	Feb 8, 2018
Grant date	Jul 20, 2021
Priority date	—
Expiry date	Feb 8, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.